urea has been researched along with HIV in 16 studies
pseudourea: clinical use; structure
isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.
HIV: Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We have discovered that nonsymmetrical cyclic ureas containing a 3-aminoindazole P2 group are potent inhibitors of HIV protease with excellent oral bioavailability." | 7.70 | Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitors. ( Anderson, PS; Bacheler, LT; Chang, CH; Cordova, B; Erickson-Viitanen, S; Garber, S; Johnson, BL; Klabe, RM; Ko, SS; Lam, PY; Li, R; Reid, C; Rodgers, JD; Ru, Y; Seitz, SP; Trainor, GL; Wang, H; Wright, MR, 1998) |
| "Two series of cyclic ureas modified at the P1/P1' residue were prepared and evaluated for HIV protease inhibition and whole cell antiviral activity." | 7.70 | The synthesis and evaluation of cyclic ureas as HIV protease inhibitors: modifications of the P1/P1' residues. ( Bacheler, LT; Cordova, BC; Erickson-Viitanen, S; Klabe, RM; Patel, M; Rayner, MM; Seitz, SP, 1998) |
| "3 h in rats and the absolute oral bioavailability ranged from 18 to 100%." | 5.29 | A pharmacokinetic evaluation of HIV protease inhibitors, cyclic ureas, in rats and dogs. ( Burcham, DL; Erickson-Viitanen, S; Grubb, MF; Huang, SM; Quon, CY; Saxton, PL; Wong, YN, 1994) |
| " The Population Council has developed a prototype intravaginal ring (IVR) releasing the non-nucleoside reverse transcriptase inhibitor (NNRTI) MIV-150 (M), zinc acetate (ZA), carrageenan (CG) and levonorgestrel (LNG) (MZCL IVR) to protect against HIV, HSV-2, HPV and unintended pregnancy." | 3.83 | A Novel Microbicide/Contraceptive Intravaginal Ring Protects Macaque Genital Mucosa against SHIV-RT Infection Ex Vivo. ( Blanchard, J; Calenda, G; Cooney, ML; Fernández-Romero, JA; Gettie, A; Kizima, L; Mizenina, O; Robbiani, M; Teleshova, N; Ugaonkar, S; Villegas, G; Zhang, S; Zydowsky, TM, 2016) |
| "We have discovered that nonsymmetrical cyclic ureas containing a 3-aminoindazole P2 group are potent inhibitors of HIV protease with excellent oral bioavailability." | 3.70 | Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitors. ( Anderson, PS; Bacheler, LT; Chang, CH; Cordova, B; Erickson-Viitanen, S; Garber, S; Johnson, BL; Klabe, RM; Ko, SS; Lam, PY; Li, R; Reid, C; Rodgers, JD; Ru, Y; Seitz, SP; Trainor, GL; Wang, H; Wright, MR, 1998) |
| "Two series of cyclic ureas modified at the P1/P1' residue were prepared and evaluated for HIV protease inhibition and whole cell antiviral activity." | 3.70 | The synthesis and evaluation of cyclic ureas as HIV protease inhibitors: modifications of the P1/P1' residues. ( Bacheler, LT; Cordova, BC; Erickson-Viitanen, S; Klabe, RM; Patel, M; Rayner, MM; Seitz, SP, 1998) |
| "SC-52151 is a potent, selective, tight-binding human immunodeficiency virus (HIV) protease inhibitor containing the novel (R)-(hydroxyethyl) urea isostere." | 3.69 | SC-52151, a novel inhibitor of the human immunodeficiency virus protease. ( Bryant, M; Clare, M; DeCrescenzo, G; Dillard, R; Getman, D; Heintz, R; Houseman, K; Lansky, D; Marr, J; Smidt, M, 1995) |
| " While the use of currently approved HIV protease inhibitors in concert with drugs that target the reverse transcriptase has dramatically ameliorated the disease state for many individuals, highly-structured dosing regimens accompanied by adverse side-effect profiles have led to a significant level of patient non-compliance." | 2.42 | Non-peptidic HIV protease inhibitors. ( Chrusciel, RA; Strohbach, JW, 2004) |
| "Mollecarbamates 1-4 are a family of compounds that possess repeating o-carboxyphenethylamide units and a carbamate moiety, while the molleureas 5-8 contain tetra- and penta-repeating carboxyphenethylamide units and a urea bridge in different positions." | 1.46 | Mollecarbamates, Molleureas, and Molledihydroisoquinolone, o-Carboxyphenethylamide Metabolites of the Ascidian Didemnum molle Collected in Madagascar. ( Aknin, M; Barrows, LR; Carmeli, S; Gauvin-Bialecki, A; Issac, M; Kashman, Y; Pond, CD, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.25) | 18.7374 |
| 1990's | 6 (37.50) | 18.2507 |
| 2000's | 4 (25.00) | 29.6817 |
| 2010's | 5 (31.25) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Issac, M | 1 |
| Aknin, M | 1 |
| Gauvin-Bialecki, A | 1 |
| Pond, CD | 1 |
| Barrows, LR | 1 |
| Kashman, Y | 1 |
| Carmeli, S | 1 |
| Pang, X | 1 |
| Liu, Z | 1 |
| Zhai, G | 1 |
| Chen, J | 1 |
| Poddar, NK | 1 |
| Tauzin, LJ | 1 |
| Cooper, D | 1 |
| Kolomeisky, AB | 1 |
| Landes, CF | 1 |
| Villegas, G | 1 |
| Calenda, G | 1 |
| Ugaonkar, S | 1 |
| Zhang, S | 1 |
| Kizima, L | 1 |
| Mizenina, O | 1 |
| Gettie, A | 2 |
| Blanchard, J | 2 |
| Cooney, ML | 1 |
| Robbiani, M | 2 |
| Fernández-Romero, JA | 1 |
| Zydowsky, TM | 2 |
| Teleshova, N | 1 |
| Pessoa-E-Silva, R | 1 |
| Mendonça Trajano-Silva, LA | 1 |
| Lopes da Silva, MA | 1 |
| da Cunha Gonçalves-de-Albuquerque, S | 1 |
| de Goes, TC | 1 |
| Silva de Morais, RC | 1 |
| Lopes de Melo, F | 1 |
| de Paiva-Cavalcanti, M | 1 |
| Crostarosa, F | 1 |
| Aravantinou, M | 1 |
| Akpogheneta, OJ | 1 |
| Jasny, E | 1 |
| Shaw, A | 1 |
| Kenney, J | 1 |
| Piatak, M | 1 |
| Lifson, JD | 1 |
| Teitelbaum, A | 1 |
| Hu, L | 1 |
| Chudolij, A | 1 |
| Kaltenbach, RF | 1 |
| Patel, M | 2 |
| Waltermire, RE | 1 |
| Harris, GD | 1 |
| Stone, BR | 1 |
| Klabe, RM | 3 |
| Garber, S | 2 |
| Bacheler, LT | 3 |
| Cordova, BC | 2 |
| Logue, K | 1 |
| Wright, MR | 2 |
| Erickson-Viitanen, S | 4 |
| Trainor, GL | 2 |
| Chrusciel, RA | 1 |
| Strohbach, JW | 1 |
| Struga, M | 1 |
| Kossakowski, J | 1 |
| Kedzierska, E | 1 |
| Fidecka, S | 1 |
| Stefańska, J | 1 |
| Delwart, EL | 1 |
| Herring, B | 1 |
| Rodrigo, AG | 1 |
| Mullins, JI | 1 |
| Wong, YN | 1 |
| Burcham, DL | 1 |
| Saxton, PL | 1 |
| Grubb, MF | 1 |
| Quon, CY | 1 |
| Huang, SM | 1 |
| Bryant, M | 1 |
| Getman, D | 1 |
| Smidt, M | 1 |
| Marr, J | 1 |
| Clare, M | 1 |
| Dillard, R | 1 |
| Lansky, D | 1 |
| DeCrescenzo, G | 1 |
| Heintz, R | 1 |
| Houseman, K | 1 |
| Rayner, MM | 2 |
| Cordova, B | 2 |
| Jackson, DA | 1 |
| Rodgers, JD | 1 |
| Lam, PY | 1 |
| Johnson, BL | 1 |
| Wang, H | 1 |
| Li, R | 1 |
| Ru, Y | 1 |
| Ko, SS | 1 |
| Seitz, SP | 2 |
| Anderson, PS | 1 |
| Reid, C | 1 |
| Chang, CH | 1 |
| Dormont, D | 1 |
| Vaslin, B | 1 |
| Dubeaux, D | 1 |
| Boussin, F | 1 |
| Maillard, F | 1 |
| Deslys, JP | 1 |
2 reviews available for urea and HIV
| Article | Year |
|---|---|
Advances in non-peptidomimetic HIV protease inhibitors.
Topics: Drug Design; Drug Resistance, Viral; Fullerenes; HIV; HIV Infections; HIV Protease; HIV Protease Inh | 2014 |
Non-peptidic HIV protease inhibitors.
Topics: Anti-HIV Agents; Disulfides; Drug Resistance, Viral; Furans; Heterocyclic Compounds, 4 or More Rings | 2004 |
14 other studies available for urea and HIV
| Article | Year |
|---|---|
Mollecarbamates, Molleureas, and Molledihydroisoquinolone, o-Carboxyphenethylamide Metabolites of the Ascidian Didemnum molle Collected in Madagascar.
Topics: Animals; Carbamates; HIV; Humans; Isoquinolines; Madagascar; Microbial Sensitivity Tests; Molecular | 2017 |
Single-molecule FRET studies of HIV TAR-DNA hairpin unfolding dynamics.
Topics: Base Sequence; Coloring Agents; DNA, Viral; Fluorescence Resonance Energy Transfer; HIV; Inverted Re | 2014 |
A Novel Microbicide/Contraceptive Intravaginal Ring Protects Macaque Genital Mucosa against SHIV-RT Infection Ex Vivo.
Topics: Animals; Anti-Infective Agents; Carrageenan; Contraceptive Agents, Female; Contraceptive Devices, Fe | 2016 |
Evaluation of urine for Leishmania infantum DNA detection by real-time quantitative PCR.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Aged; Brazil; Child; Creatinine; DNA, Kinetop | 2016 |
A macaque model to study vaginal HSV-2/immunodeficiency virus co-infection and the impact of HSV-2 on microbicide efficacy.
Topics: Animals; Anti-Infective Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Chlorocebus | 2009 |
Synthesis, antiviral activity and pharmacokinetics of P1/P1' substituted 3-aminoindazole cyclic urea HIV protease inhibitors.
Topics: Administration, Oral; Animals; Biological Availability; Dogs; Drug Resistance; Heterocyclic Compound | 2003 |
Synthesis and pharmacological activity of urea and thiourea derivatives of 4-azatricyclo[5.2.2.0(2,6)]undec-8-ene-3,5-dione.
Topics: Animals; Anti-HIV Agents; Anti-Infective Agents; Anticonvulsants; Antineoplastic Agents; Behavior, A | 2007 |
Genetic subtyping of human immunodeficiency virus using a heteroduplex mobility assay.
Topics: Acquired Immunodeficiency Syndrome; Base Sequence; DNA Primers; DNA, Single-Stranded; DNA, Viral; El | 1995 |
A pharmacokinetic evaluation of HIV protease inhibitors, cyclic ureas, in rats and dogs.
Topics: Administration, Oral; Animals; Biological Availability; Chromatography, High Pressure Liquid; Comput | 1994 |
SC-52151, a novel inhibitor of the human immunodeficiency virus protease.
Topics: Amino Acid Sequence; Animals; Antiviral Agents; Dogs; Drug Synergism; HIV; HIV Protease Inhibitors; | 1995 |
Population dynamics studies of wild-type and drug-resistant mutant HIV in mixed infections.
Topics: Alkynes; Azepines; Benzoxazines; Cyclopropanes; Drug Resistance, Microbial; HIV; HIV Infections; HIV | 1997 |
Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitors.
Topics: Animals; Anti-HIV Agents; Crystallography, X-Ray; Dogs; Drug Design; HIV; HIV Protease Inhibitors; M | 1998 |
The synthesis and evaluation of cyclic ureas as HIV protease inhibitors: modifications of the P1/P1' residues.
Topics: Antiviral Agents; Azepines; HIV; HIV Protease; HIV Protease Inhibitors; Indicators and Reagents; Kin | 1998 |
Inactivation of human immunodeficiency virus during human growth hormone production.
Topics: Antiviral Agents; Cells, Cultured; Drug Contamination; Ethanol; Growth Hormone; HIV; Humans; Hydroge | 1988 |